NCT03540407View on ClinicalTrials.gov

Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

February 1, 2019

Study Completion Date

September 30, 2019

Conditions
Cervical Carcinoma Stage IICervical Carcinoma Stage IIICervical Carcinoma Stage IVEndometrial Adenocarcinoma Stage IIEndometrial Adenocarcinoma Stage IIIEndometrial Adenocarcinoma Stage IV
Interventions
DIETARY_SUPPLEMENT

Oncoxin-Viusid®

Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment

DIETARY_SUPPLEMENT

Placebo

Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment

Trial Locations (1)

10400

Ramón González Coro Hospital, La Habana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03540407 - Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | Biotech Hunter | Biotech Hunter